Market Size of Global NGS Sample Preparation Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 12.40 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
NGS Sample Preparation Market Analysis
The NGS sample preparation market is expected to register a CAGR of 12.4% over the forecast period.
The outbreak of the COVID-19 pandemic has impacted the NGS sample preparation market. The increasing coronavirus cases worldwide led to the need to develop effective and quick sequencing technologies to rebuild the genomic sequence of SARS-CoV-2, which was the etiological agent of COVID-19. It was critical in the development of diagnostic molecular tests as well as the development of efficient tactics and strategies to slow the spread of the pandemic. For instance, in August 2020, Helix Laboratory received the U.S. FDA emergency use authorization for NGS based COVID-19 test, which is designed to detect the SARS-CoV-2 spike protein gene in upper respiratory specimens. This next-generation sequencing was applied
for the study of COVID-19 and has greatly promoted SARS-CoV-2 original tracking. Since next-generation sequencing (NGS) sample preparation played a vital role during the pandemic, thus the market witnessed positive growth and is expected to continue the upward trend over the forecast period.
The rising infectious disease prevalence reduced sequencing cost, and technical advancement in NGS platforms are the major factors propelling the market growth. With the increasing prevalence of infectious diseases, NGS sequencing technologies have swiftly become the method of choice in virology for a wide range of applications, including the detection of novel viruses from metagenomic samples, reconstruction of whole or almost complete viral genome sequences, and viral evolution and subspecies analysis. For instance, as per the WHO August 2022 Influenza Update, National Influenza Centers (NICs) and other national influenza laboratories from 120 countries, regions, or territories submitted data to FluNet from 11 July 2022 to 24 July 2022. Over 145,086 samples were analyzed by the WHO Global Influenza Surveillance and Response System (GISRS) laboratories during that time. Among the 6,449 people who tested positive for influenza viruses, 97.7% had influenza A, and 2.3% had influenza B.
Similarly, according to the WHO report 2021, each year, typhoid fever is estimated to affect 21 million people worldwide. Similarly, according to the CDC, 30,000 cases of yellow fever occur annually, out of which 90.0% occur in Africa. Therefore, increasing cases of infectious diseases across the globe is anticipated to propel market growth over the forecast period.
The key and small players' launch of new NGS technologies drive market growth. NGS technologies have replaced traditional sequencing methods because of the low cost and high sequencing efficiency. For instance, according to Illumina, in 2021, the cost of next-generation sequencing (NGS) has decreased dramatically since the completion of the Human Genome Project. Illumina has helped reduce the cost of NGS, enabling the USD 1000 human genome. Therefore, new product launches are expected to surge the market growth over the forecast period.
However, the high costs of NGS sample preparation equipment and strict regulation associated with NGS Sample preparation are likely to impede the market growth.
